Loading...

Kintara Therapeutics, Inc.

KTRANASDAQ
HealthcareBiotechnology
$0.22
$-0.01(-6.31%)

Kintara Therapeutics, Inc. (KTRA) Stock Overview

Explore Kintara Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
$-0.31
41.97%
EPS Growth
$-0.31
64.27%
Operating Margin
5468.42%
42.58%
ROE
-251.68%
41.97%
Dividend Yield
0.00%
53.89%
Analyst Recommendations data is not available for KTRAAnalyst Recommendations details for KTRA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

CEO

Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Employees

1

Headquarters

12707 High Bluff Drive, San Diego, CA

Founded

2013

Frequently Asked Questions